Modulating NASH Fibrosis by Attacking Upstream Metabolic Targets

• All-cause mortality is linked to cirrhosis. Many studies are now focusing on liver drugs with pleiotropic and/or antifibrotic effects.
• Efruxifermin (FGF21 agonist) has shown significant results in nonalcoholic steatohepatitis (NASH) resolution and fibrosis improvement. Pegozafermin has shown improvement in fibrosis without worsening NASH in 45% of the patients with F4 fibrosis.
• Lanifibranor a pan-PPAR agonist has been shown to improve NASH histology. Semaglutide has also been shown to improve NASH resolution. ALPINE 4 is a recent ongoing trial that will give more insights into NASH cirrhosis.